Edward H. Romond, MD

Clinical interests

  • Adult Hemophilia
  • Breast Cancer
  • Medical Oncology

Edward H. Romond, MD

Biography

My name is Edward Romond; I received my medical degree from the University of Kentucky, College of Medicine, Lexington. I completed a fellowship at Michigan State University, East Lansing. I am a recipient of The Leonard Tow 2003 Humanism in Medicine Award.

I am board certified by the American Board of Internal Medicine in Hematology and Medical Oncology.

Faculty rank

Professor of Medicine

Education

Degree
University of Kentucky, College of Medicine, Lexington

Residency
Michigan State University Associated Hospitals, Lansing

Fellowship
Michigan State University, East Lansing

Certifications or Special training
American Board of Internal Medicine
American Board of Internal Medicine, Hematology
American Board of Internal Medicine, Medical Oncology
The Leonard Tow 2003 Humanism in Medicine Award

Breast Care

Comprehensive Breast Care Center

Markey Cancer Center
Whitney-Hendrickson Building
Second Floor
800 Rose St.
Lexington KY 40536-0098

HBCicon120x123
This is a clinic of the University of Kentucky Hospital, also known as UK Albert B. Chandler Hospital. Read more »

Call 859-323-2222
Call 866-340-4488
Fax 859-323-6109

Diagnostic Technologies: Diagnostic Mammography, Tomosynthesis, US

Directions to Markey Cancer Center »



Medical Oncology

Comprehensive Breast Care Center

Markey Cancer Center
Whitney-Hendrickson Building
Room 232
800 Rose St.
Lexington KY 40536-0098

Call 859-323-2222
Call 859-323-8043
Fax 859-257-3757

Directions to Markey Cancer Center »


UK HealthCare accepts many forms of insurance. See list of insurers »

 

Recent Publications

(Five most recent publications from PubMed via an automated list based on the provider’s ID and the University of Kentucky.)
  1. Hilal T, Romond EH.
    ERBB2 (HER2) Testing in Breast Cancer.
    JAMA. 315(12):1280-1.
  2. Cecchini RS, Swain SM, Costantino JP, Rastogi P, Jeong JH, Anderson SJ, Tang G, Geyer CE, Lembersky BC, Romond EH, Paterson AH, Wolmark N.
    Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38.
    Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):51-9.
  3. Jatoi I, Bandos H, Jeong JH, Anderson WF, Romond EH, Mamounas EP, Wolmark N.
    Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.
    J Natl Cancer Inst. 2016 Jan;108(1).
  4. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N.
    Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
    J Clin Oncol. 2014 Nov 20;32(33):3744-52.
  5. Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE, Costantino JP, Wolmark N, Paik S.
    Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
    J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8.

View this provider on PubMed